Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6U9M

MLL1 SET N3861I/Q3867L bound to inhibitor 16 (TC-5109)

Summary for 6U9M
Entry DOI10.2210/pdb6u9m/pdb
Related6U9K
DescriptorHistone-lysine N-methyltransferase, ZINC ION, 5'-{[(3S)-3-amino-3-carboxypropyl]({1-[(thiophen-2-yl)methyl]azetidin-3-yl}methyl)amino}-5'-deoxyadenosine, ... (5 entities in total)
Functional Keywordstransferase, transferase-transferase inhibitor complex, transferase/transferase inhibitor
Biological sourceHomo sapiens (Human)
Total number of polymer chains2
Total formula weight37774.53
Authors
Petrunak, E.M.,Stuckey, J.A. (deposition date: 2019-09-09, release date: 2020-07-01, Last modification date: 2023-10-11)
Primary citationChern, T.R.,Liu, L.,Petrunak, E.,Stuckey, J.A.,Wang, M.,Bernard, D.,Zhou, H.,Lee, S.,Dou, Y.,Wang, S.
Discovery of Potent Small-Molecule Inhibitors of MLL Methyltransferase.
Acs Med.Chem.Lett., 11:1348-1352, 2020
Cited by
PubMed Abstract: The mixed-lineage leukemia (MLL) protein, also known as MLL1, is a lysine methyltransferase specifically responsible for methylation of histone 3 lysine 4. MLL has been pursued as an attractive therapeutic target for the treatment of acute leukemia carrying the MLL fusion gene or MLL leukemia. Herein, we report the design, synthesis, and evaluation of an -adenosylmethionine-based focused chemical library which led to the discovery of potent small-molecule inhibitors directly targeting the MLL SET domain. Determination of cocrystal structures for a number of these MLL inhibitors reveals that they adopt a unique binding mode that locks the MLL SET domain in an open, inactive conformation.
PubMed: 32551023
DOI: 10.1021/acsmedchemlett.0c00229
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.05 Å)
Structure validation

227344

PDB entries from 2024-11-13

PDB statisticsPDBj update infoContact PDBjnumon